PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-53.09%
Negative ROE indicates either losses or negative equity – a major Benjamin Graham warning. Confirm if leverage or poor profitability is the cause.
-39.15%
Negative ROA indicates net losses or excessive assets. Benjamin Graham would question viability or capital misallocation.
-53.52%
Negative ROCE suggests negative EBIT or an inflated capital base. Benjamin Graham would check if the firm is structurally unprofitable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.